Case Report
Summary of COVID-19 vaccine-related erythema multiforme at Kindai University Hospital, Japan
Received: 05 September 2024
Published: 14 December 2022
Abstract
The recently extended use of mRNA vaccines due to the COVID-19 pandemic has allowed the description of multiple cutaneous adverse events including local injection site reactions, urticaria, and morbilliform eruptions. COVID-19 vaccine-related cutaneous reaction patterns can be divided into type Ⅰ hypersensitivity reactions, type Ⅳ hypersensitivity reactions, autoimmune-related, and functional angiopathies based on pathogenesis. Erythema multiforme (EM), a type IV hypersensitivity reaction, has also been reported from several centers. We experienced the remarkable improvement of COVID-19 vaccine-related EM with systemic administration of prednisolone and summarized six cases experienced in our department.
Keywords
References
- 1. Gambichler T, Boms S, Susok L, et al. Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience. Journal of the European Academy of Dermatology and Venereology 2022; 36(2): 172–180. doi: 10.1111/jdv.17744.
- 2. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology 2021; 85(1): 46–55. doi: 10.1016/j.jaad.2021.03.092.
- 3. Grieco T, Maddalena P, Sernicola A, et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. Dermatologic Therapy 2021; 34(6): e15153. doi: 10.1111/dth.15153.